GlassScriptPhysician profile
Jody Kirk
NPI 1457657926
$3,251.09
in general payments reported to CMS, 2019-2025
19 companies · $803 in 2025
The $803 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $573 · 2022: $377 · 2023: $662 · 2024: $837 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,300.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,199.23 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $523.98 | 2021-2025 | |
| Lilly USA, LLC | $332.86 | 2021-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $314.55 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $195.57 | 2021-2025 | Farxiga, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $136.03 | 2021-2024 | Shingrix, Bexsero, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $99.77 | 2025 | Caplyta |
| Exact Sciences Corporation | $84.49 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $81.22 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $69.65 | 2022-2025 | Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $56.29 | 2022 | |
| Amgen INC. | $30.95 | 2021 | |
| Medtronic, INC. | $22.57 | 2023 | Intellis Adaptivestim |
| Ultragenyx Pharmaceutical INC. | $21.99 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.06 | 2024 | Jardiance |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $18.83 | 2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.48 | 2024 | Xifaxan |
| Lundbeck LLC | $14.65 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jody Kirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.